Would pan-tuberculosis treatment regimens be cost-effective?

Emily Kendall, Grania Brigden, Christian Lienhardt, David Wesley Dowdy

Research output: Contribution to journalArticle

Original languageEnglish (US)
JournalThe Lancet Respiratory Medicine
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Tuberculosis
Costs and Cost Analysis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Would pan-tuberculosis treatment regimens be cost-effective? / Kendall, Emily; Brigden, Grania; Lienhardt, Christian; Dowdy, David Wesley.

In: The Lancet Respiratory Medicine, 01.01.2018.

Research output: Contribution to journalArticle

@article{cf27de7157fd43189a2832cc06f26e7f,
title = "Would pan-tuberculosis treatment regimens be cost-effective?",
author = "Emily Kendall and Grania Brigden and Christian Lienhardt and Dowdy, {David Wesley}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/S2213-2600(18)30197-8",
language = "English (US)",
journal = "The Lancet Respiratory Medicine",
issn = "2213-2600",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Would pan-tuberculosis treatment regimens be cost-effective?

AU - Kendall, Emily

AU - Brigden, Grania

AU - Lienhardt, Christian

AU - Dowdy, David Wesley

PY - 2018/1/1

Y1 - 2018/1/1

UR - http://www.scopus.com/inward/record.url?scp=85047605957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047605957&partnerID=8YFLogxK

U2 - 10.1016/S2213-2600(18)30197-8

DO - 10.1016/S2213-2600(18)30197-8

M3 - Article

C2 - 29859919

AN - SCOPUS:85047605957

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

SN - 2213-2600

ER -